Business Context and Reporting Period
This Form 8-K was filed by PerkinElmer, Inc. (now known as Revvity, Inc.) on June 12, 2009. The report discloses the entry into a material definitive agreement regarding an international acquisition.
Key Financial Metrics and Transaction Details
- Transaction Type: Acquisition of 100% of outstanding equity interests in Shanghai Sym-BioLifeSciences Co., Ltd. ("Sym-Bio").
- Acquirer: PerkinElmer IVD Pte. Ltd. ("PKI Singapore"), a Singapore subsidiary of PerkinElmer, Inc.
- Target: Sym-Bio, described as a leading Chinese diagnostic product company.
- Consideration: Cash payment of RMB 435.0 million.
- Payment Terms: Subject to the establishment of escrow accounts to secure potential claims.
- Parent Company Role: PerkinElmer, Inc. acts solely as a guarantor for PKI Singapore's obligations.
Material Changes and Conditions
The filing does not report changes to historical revenue, profit, or cash flow for a specific reporting period. The material change is the pending acquisition, which is subject to regulatory approvals and customary closing conditions. The transaction is expected to close in the third quarter of 2009.
Outlook, Risks, and Contingencies
- Closing Contingency: Completion depends on regulatory approvals and other customary conditions.
- Legal Protections: The agreement includes representations, warranties, covenants, and indemnification provisions for breaches.
- Financial Security: Escrow accounts will be established to secure potential claims under the agreement.
Investor Verification Checklist
- Verify the final closing date and whether regulatory approvals were obtained in Q3 2009.
- Confirm the actual cash consideration paid versus the stated RMB 435.0 million.
- Review subsequent filings for any adjustments to the purchase price or indemnification claims.
- Assess the financial impact of the acquisition on PerkinElmer's consolidated balance sheet post-closing.